对帕金森病的药物重新定位:强调人工智能方法
Iman Karimi-Sani1, Mehrdad Sharifi2, Nahid Abolpour3
1Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Ageing research reviews
|January 4, 2025
概括
人工智能 (AI) 正通过药物重新定位来彻底改变帕金森病 (PD) 治疗. 人工智能/机器学习 (AI/ML) 的进步提高了PD的药物发现和临床试验规划.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 帕金森病 (PD) 是一种主要的神经退行性疾病 (NDD),影响65岁以上的人群中的1-2%.
- 药物重新定位为开发新型PD治疗提供了一个有希望的途径,通过重新定位现有或被置的药物来开发新的PD治疗方法.
研究的目的:
- 审查最近在帕金森病药物重新定位方面的进展.
- 评估人工智能 (AI) 和机器学习 (AI / ML) 在PD药物发现和临床试验优化中的当前作用和未来潜力.
主要方法:
- 在Web of Science,Scopus和PubMed进行了全面的文献搜索.
- 从1975年到现在的数据被审查,以确定用于PD重新定位的药物.
- 分析了计算方法的当前状态,包括PD治疗中的AI/ML.
主要成果:
- 最近,对帕金森病的药物重新定位研究显著增加.
- 人工智能/ML算法显著提高了PD药物发现的成功率.
- 科学界对药物重新定位对有效的PD治疗替代品越来越感兴趣.
结论:
- 对帕金森病的药物重新定位正在获得动力,这得益于AI/ML的进步.
- 将人工智能集成到临床试验规划中,对于提高试验有效性至关重要.
- 迫切需要基于人工智能的创新解决方案,以提高PD药物开发的整体成功率.
相关概念视频
Parkinson's Disease: Treatment
215
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
215
Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K


